Autologous platelet lysate for treatment of refractory ocular GVHD

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmers test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as responders when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.

Original languageEnglish
Pages (from-to)1558-1563
Number of pages6
JournalBone Marrow Transplantation
Volume47
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Blood Platelets
Tears
Therapeutics
Photophobia
Ophthalmic Solutions
Immunosuppressive Agents
Fluorescein
Visual Acuity
Signs and Symptoms
Adrenal Cortex Hormones
Staining and Labeling
Safety

Keywords

  • allo-SCT
  • dry eye syndrome
  • GVHD
  • ocular GVHD
  • PDGFs
  • plasma rich in growth factors

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous platelet lysate for treatment of refractory ocular GVHD. / Pezzotta, S.; Fante, C. Del; Scudeller, L.; Cervio, M.; Antoniazzi, E. R.; Perotti, C.

In: Bone Marrow Transplantation, Vol. 47, No. 12, 12.2012, p. 1558-1563.

Research output: Contribution to journalArticle

@article{b078d3485ea044399711a24d7da76a12,
title = "Autologous platelet lysate for treatment of refractory ocular GVHD",
abstract = "Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmers test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as responders when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9{\%}) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6{\%}). TBUT improved in 20 patients (86.9{\%}) and anterior segment score in 19 patients (82.6{\%}). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.",
keywords = "allo-SCT, dry eye syndrome, GVHD, ocular GVHD, PDGFs, plasma rich in growth factors",
author = "S. Pezzotta and Fante, {C. Del} and L. Scudeller and M. Cervio and Antoniazzi, {E. R.} and C. Perotti",
year = "2012",
month = "12",
doi = "10.1038/bmt.2012.64",
language = "English",
volume = "47",
pages = "1558--1563",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Autologous platelet lysate for treatment of refractory ocular GVHD

AU - Pezzotta, S.

AU - Fante, C. Del

AU - Scudeller, L.

AU - Cervio, M.

AU - Antoniazzi, E. R.

AU - Perotti, C.

PY - 2012/12

Y1 - 2012/12

N2 - Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmers test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as responders when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.

AB - Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmers test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as responders when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.

KW - allo-SCT

KW - dry eye syndrome

KW - GVHD

KW - ocular GVHD

KW - PDGFs

KW - plasma rich in growth factors

UR - http://www.scopus.com/inward/record.url?scp=84870775970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870775970&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.64

DO - 10.1038/bmt.2012.64

M3 - Article

VL - 47

SP - 1558

EP - 1563

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -